Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
December 23, 2024 16:49 ET | Source: Neuphoria Therapeutics, Inc. BURLINGTON, Mass.,…
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 20, 2024 17:00 ET | Source: Iovance Biotherapeutics, Inc. SAN CARLOS,…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2024 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 20, 2024 17:00 ET | Source: Iovance Biotherapeutics, Inc. SAN CARLOS,…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2024 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 20, 2024 17:00 ET | Source: Iovance Biotherapeutics, Inc. SAN CARLOS,…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2024 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Dentsply Sirona, Inc. (NASDAQ: XRAY)
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and…
Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE,…
Cerence AI Announces Equity Grant to Employee Under Inducement Plan Pursuant to Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC)…